Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
Rectification order restores ₹65.48 cr in tax losses for subsidiary Jubilant Generics, but the company continues to appeal the remaining amount on merits.
— 9 earlier stories on Jubilant Pharmova Ltd. →What's new
- Income tax department reduces transfer pricing adjustment to ₹42.41 cr from ₹107.89 cr.
- Rectification order restores ₹65.48 cr in tax losses for the subsidiary.
- Company continues to appeal the remaining amount before CIT(A).
Why this matters
The ₹65.48 cr reduction eases the tax overhang, but the remaining ₹42.41 cr (10.7% of FY26 net profit) is still under dispute. With two FDA actions in May and June, the company's regulatory plate is full.
What we're watching
- Outcome of the appeal before CIT(A) for the remaining demand.
- Impact on Jubilant's cash flows and provisions.
- Whether further rectifications or settlements occur.
The full read
Jubilant Pharmova's step-down subsidiary Jubilant Generics just got a ₹65.48 crore break. A rectification order from the income tax department slashed a transfer pricing demand from ₹107.89 crore to ₹42.41 crore for assessment year 2023-24. It also restored tax losses of the same amount. Still contested. The remaining ₹42.41 crore is on the table, and the company is contesting it before the appellate authority. That sum represents about 10.7% of FY26 net profit. It is small enough to not trigger a re-rating, but large enough to matter for cash flows. And alongside two FDA actions in the past month (an 8-observation Form 483 at Spokane and a Warning Letter at Montreal), the company has regulatory challenges on two fronts. The tax reduction is a positive footnote, not the headline it would have been before the FDA actions.
Questions answered
- How much did the tax demand reduce?
- Reduced by ₹65.48 cr from ₹107.89 cr to ₹42.41 cr.
- What does the rectification order restore?
- It restores tax losses of ₹65.48 cr for the subsidiary.
- Is the remaining amount still contested?
- Yes, the company is pursuing an appeal on merits before the Commissioner of Income Tax (Appeals).
- What is the significance of the remaining ₹42.41 cr?
- It represents about 10.7% of FY26 net profit, material but not a valuation-changer.
- Has the company disclosed any other recent regulatory issues?
- Yes, the company's Spokane plant received 8 FDA observations and the Montreal plant received a Warning Letter.
Jubilant Pharmova Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLPHARMA →- 24 Jun 2026 · 4:49 PM IST Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
- 6d ago Jubilant Pharmova's ₹53.37 cr tax setback
- 17d ago Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
- 38d ago USFDA hits Jubilant's Montreal plant with a Warning Letter
- 45d ago Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand